EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting YY1-DR5 Axis by Pyripyropene O as a Novel Therapeutic Strategy Against Prostate Cancer: Molecular Mechanisms and In Vivo Zebrafish Validation

Wenxuan Fang, Ying Chen, Mingyi Nie, Xuefeng Zhou iD, Yonghong Liu iD, Huaming Tao iD, Bin Yang iD, Xueni Wang iD

Marine Drugs · 2025

DOI: 10.3390/md23050214 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Marine Drugs, 2025. Verfasst von Wenxuan Fang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Guangxi Engineering Research Center for High-Value Utilization of Guangxi-Produced Authentic Medicinal Herbs, Institute of Traditional Chinese and Zh…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Antineoplastic Agents, Sesquiterpenes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Guangxi, Foundation of Guangxi Key Laboratory of Marine Drugs, National Key R&D Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Induction of apoptosis is an important strategy for the treatment of prostate cancer. DR5 is a member of the death receptor superfamily and targeting DR5 is an effective way to induce apoptosis. Pyripyropene O is a natural compound isolated from the marine fungus Aspergillus fumigatus SCSIO 41220. We found it has anti-prostate cancer potential by inducing apoptosis; Methods: The effects of pyripyropene O on the viability, proliferation, cell cycle, apoptosis and migration of prostate cancer cells were investigated by MTT assay, plate clone formation assay, 3D cell sphere assay, flow cytometry and real-time cell analysis. Transmission electron microscopy was used to observe the changes in the internal structure of prostate cancer cells after treatment with pyripyropene O. After determining the mode of cell death, the mechanism of action of pyripyropene O on prostate cancer was further investigated using apoptotic protein microarray, western blot, qPCR, molecular docking, cellular immunofluorescence staining and cellular thermal shift assay. After explaining the mechanism of action of pyriproxyfen O, the in vivo absorption, distribution, metabolism, excretion and potential toxicity of pyriproxyfen O were investigated using ADMETLab 2.0 software. Finally, a zebrafish xenograft tumour model was developed to evaluate the anti-prostate cancer effects of pyriproxyfen O in vivo; Results: The experimental results at the cellular level showed that pyripyropene O inhibited the survival, proliferation and migration of prostate cancer cells, and also showed that pyripyropene O blocked the prostate cancer cell cycle at the G2/M phase and induced apoptosis. At the molecular level, pyripyropene O binds to the transcription factor YY1, promotes YY1 nuclear translocation, regulates the transcription level of DR5, a target gene of YY1, and upregulates the expression of DR5 mRNA and protein. The in vivo results showed that pyripyropene O effectively inhibited the development of prostate cancer in zebrafish; Conclusions: Pyripyropene O has a clear anti-prostate cancer effect at both cellular and animal levels, inhibiting the survival and proliferation of prostate cancer cells by binding to the transcription factor YY1 to activate the expression of DR5 to promote apoptosis, thus exerting an inhibitory effect on prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsAntineoplastic AgentsSesquiterpenesAnimalsZebrafishMaleHumansApoptosisCell Line, TumorCell ProliferationMolecular Docking SimulationCell MovementAspergillus fumigatusCell Survival

Stichwörter der Autor:innen

Ying Yang 1apoptosisdeath receptor 5prostate cancerpyripyropene O

Substanzen

Antineoplastic AgentsSesquiterpenes

Autor:innen und Institutionen

  • Guangxi Engineering Research Center for High-Value Utilization of Guangxi-Produced Authentic Medicinal Herbs, Institute of Traditional Chinese and Zhuang-Yao Ethnic Medicine, Guangxi University of Chinese Medicine, Nann…
  • Guangxi Key Laboratory of Marine Drugs, Institute of Marine Drugs, Guangxi University of Chinese Medicine, Nanning 530200, China.
  • Guangdong Key Laboratory of Marine Materia Medica/State Key Laboratory of Tropical Oceanography, South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou 510301, China.
  • School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China.

ORCID-Profile: Xuefeng Zhou, Yonghong Liu, Huaming Tao, Bin Yang, Xueni Wang

Förderung

  • Natural Science Foundation of Guangxi
  • Foundation of Guangxi Key Laboratory of Marine Drugs
  • National Key R&D Program of China
  • Innovation Project of Guangxi Graduate Education of GXUCM
  • Guangzhou Science and Technology Project
  • National Natural Science Foundation of China
  • Guangdong Basic and Applied Basic Research Foundation
  • National Key R&D Program of China

Zitieren

APA

Fang, W., Chen, Y., Nie, M., Zhou, X., Liu, Y., Tao, H., Yang, B., & Wang, X. (2025). Targeting YY1-DR5 Axis by Pyripyropene O as a Novel Therapeutic Strategy Against Prostate Cancer: Molecular Mechanisms and In Vivo Zebrafish Validation. Marine Drugs. https://doi.org/10.3390/md23050214

Vancouver

Fang W, Chen Y, Nie M, Zhou X, Liu Y, Tao H, et al. Targeting YY1-DR5 Axis by Pyripyropene O as a Novel Therapeutic Strategy Against Prostate Cancer: Molecular Mechanisms and In Vivo Zebrafish Validation. Marine Drugs. 2025. doi:10.3390/md23050214

BibTeX
@article{Fang2025,
  author = {Fang, Wenxuan and Chen, Ying and Nie, Mingyi and Zhou, Xuefeng and Liu, Yonghong and Tao, Huaming and Yang, Bin and Wang, Xueni},
  title = {Targeting YY1-DR5 Axis by Pyripyropene O as a Novel Therapeutic Strategy Against Prostate Cancer: Molecular Mechanisms and In Vivo Zebrafish Validation},
  journal = {Marine Drugs},
  year = {2025},
  doi = {10.3390/md23050214}
}
Kostenlos starten →